Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambroxol for Parkinson's disease
ISRCTN93097821Phase 3Recruiting
- Sponsor
- University College London
- Start
- Feb 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ambroxol in Parkinson's disease (PD), sponsored by University College London. Primary endpoint: Change in MDS-UPDRS Parts I-III total score. Started Feb 2025; status: recruiting.
02
Drugs
ambroxol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ISRCTN93097821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN93097821.